274 results
8-K
EX-99.1
JAZZ
Jazz Pharmaceuticals plc
1 May 24
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results
4:06pm
in support of our key growth drivers, investment in our priority programs and litigation costs.
Research and development (R&D) expenses increased in 1Q24
8-K
EX-99.1
JAZZ
Jazz Pharmaceuticals plc
28 Feb 24
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results
4:06pm
adjusted basis, in 4Q23 included lower compensation-related and litigation expenses compared to 4Q22.
Research and development (R&D) expenses increased
8-K
EX-10.1
JAZZ
Jazz Pharmaceuticals plc
25 Jan 24
Entry into a Material Definitive Agreement
5:01pm
No Material Adverse Effect
Section 3.07
Title to Properties; Possession Under Leases
Section 3.08
[Reserved]
Section 3.09
Litigation; Compliance …
Litigation and Other Notices
Section 5.06
Compliance with Laws
Section 5.07
Maintaining Records; Access to Properties and Inspections
Section 5.08
Use
8-K
EX-99.1
6rigy04 vi34
9 Aug 23
Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance
4:07pm
8-K
ol80yv 3uuqtc49d
22 Jun 23
Regulation FD Disclosure
4:05pm
8-K
EX-2.1
2wlqnir0dlt itvigwc
5 Dec 22
Completion of Acquisition or Disposition of Assets
4:16pm
8-K
EX-99.1
ys0a4v15 onvy63
7 Apr 22
Other Events
7:15am